Detail akcie Vericel online

Business Summary: Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Vericel Corp revenues increased 20% to $197.5M. Net loss decreased 81% to $3.2M. Revenues reflect MACI segment increase of 25% to $164.8M, NexoBrid segment increase of 71% to $1.1M. Lower net loss reflects Stock-based Compensation in SGA decrease of 87% to $3.7M (expense), Interest income increase from $1.3M to $4.6M (income).